| Name | Title | Contact Details |
|---|
We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.
Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
Apeel Sciences creates products from natural plant extracts that allow growers to reduce reliance on pesticides, increase produce quality, and provide superior shelf life without refrigeration.
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families.
Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.